Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | TP53 | P04637 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651979 | 0.87 | MAPT (0.55) | MAPTTP53TDP1LMNAPPARG | |
| SCHEMBL2650795 | 0.77 | PPARG (0.47) | MAPTTP53PPARG | |
| SCHEMBL2652219 | 0.76 | GCGR (0.50) | PPARGTBXA2RDRD2 | |
| SCHEMBL2651771 | 0.74 | GCGR (0.44) | TDP1PPARGTBXA2RDRD2 | |
| SCHEMBL2652187 | 0.74 | HDAC1 (0.54) | MAPTTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL2655339 | 0.74 | HDAC1 (0.46) | TP53PPARGTBXA2REGLN1DRD2 | |
| SCHEMBL2652185 | 0.73 | GCGR (0.60) | — | |
| SCHEMBL2653126 | 0.72 | HDAC1 (0.61) | MAPTTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL2655061 | 0.72 | PTGDR2 (0.46) | MAPTTP53ALDH1A1PPARG | |
| SCHEMBL9256074 | 0.70 | ITGB3 (0.54) | ALDH1A1PPARGTBXA2REGLN1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | THRB 44/4885MAPT 4512/4885TP53 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.